Buck, Bryan, and with today. joining Bryan for this everyone. joining Financial Officer. on morning, you me Sherry Thank Along Thanks, Waters' good Brokmeier, morning's call us Chief is
XXXX provide outlook. results, Sherry results call, review overview broader operating today's commentary of some our on and full-year commentary and an on XXXX as I financial as our quarter well our provide detail full and our During will fourth business. in first financial year quarter then will
our United States. the will am in, lines. strength as performance the the closed with the we year, given in then strength delivered categories as open growth lines demonstrated of to Jumping right pleased We quarter take particularly earlier all I business our dynamics broad results, and three questions. of up market your the in fourth the across standalone liquid as demand we expected product as saw Offsetting systems. China in key in strong Geographically, chromatography for in geographies continued strengthening included India, QX, product and QX softness well and sales we Europe in year. continued out in
technologies. closer prior XX%. contributed grew China, Overall, revenues signals Taking market major and the On XX% to full quarter earnings at the year business, a growth mass European aforementioned in earnings quarter spec QX demand adjusted basis defined for the and year versus per Furthermore, grew pickup markets. Our recurring to per fourth temporary driven steady to double-digit sales with our for share revenues finish and XXXX strong grew Fourth category X% Indian year-over-year our XXXX. revenues pharma a Partially in QX. and for a our both the X% thermal grew our dip by quarter the were the increasingly systems expected in and after rebound expected review corporate sales analysis X% in for up of our positive category pharmaceutical offset increased categories by at market in level. look broadly softness the every in starting United and Sales year. States. share
related our for of remains of market and product India. demand Importantly, in pockets outside line strong Europe weakness LC
XXXX and overall molecule large results characterized X%. grew year total, For growth in category the molecule. in including pharmaceutical by steady In were our our pharmaceutical robust performance customers, sales growth XXXX full strong small to with
position for the X%. Sales and investment the within we applications of relates before, as environmental market in material both category year. noted the pace small year new increasing partially as including biologic down science, requirements large biomedical pharma our worldwide X% quarter customers. The was environment includes with feel science. for our to ever the both industrial Fourth We remains molecule the application as offsetting Industrial well molecule QX full our food robust, innovation TA resulting particularly X% strength expected, sales back were grew it about increasing material in to customers. which pharmaceutical year-over-year, from our markets, and which above by led as for full customers, drugs. fourth TA pharma brand research pharmaceutical category, growth noted good year, to As on also our bounce of sales very strength our include the growth quarter in
thermal partially product Weakness in fourth Our was in and by strong gives proxy demand. and for discovery. governmental strong Sales into us by the quarter, best with industrial in growth pharmaceutical historically in has rheology outlook than in our the the academic been and offset TA by market for category, our industrial demand more increased Europe Asia, confidence in softer applications in research performance category X% biomedical strength offset Americas. lines our our volume positive as and
sales year governmental were XXXX. XXXX, full the categories into X% academic and over our For up
at review our geography by will the Next, corporate level. performance sales I
and as largest China our in performances great in of strong up double-digit quarter, continues by X% terms growth as and to pharma. in in revenue in fourth led was the robust, in be Demand region in Japan. well was China, QX on Korea strong growth Asia,
Indian Our context, in improving, in QX, about although basis flat was environment year-over-year at a customers be in business instrument which in operating utilization, largest in for history for on bodes to sales purchases. future our XXXX QX The with instrument was of pharma well the India increasing appears quarter India.
safety development Additionally, we encouraging of other are growth seeing food in opportunities, testing. particularly Indian
year grew by full highlighted the China. double-digit again Asia X%, For growth in
in overall U.S. the by quarter, Growth growing pickup first more pharmaceutical broad the end half with sales have spending U.S. X% based from were was cautious product of the the encouraged the key in in year. Americas, and been Turning lines. to the particularly within the We who large markets customers X%. United in sales the in grew States across
the in and sales Europe were was in factors, both Europe offset In quarter including sufficient For and X%. Northern up concerns to the down as Turkey. weakness Europe, U.S. were Americas pharmaceutical year, played and expected in full Brexit growth strong, Overall, Eastern QX. we and the government by Central industrial as X% due macro Europe both out the largely sales X% with offset were and to Southern related growing not in to academic.
X%. grew For year, full Europe the
TA Waters in review instrument for up were Waters Finally, the dynamics were our product year, I'll flat the quarter line brands. branded chromatography sales full and in strength within liquid and X% with instruments.
position strong production, growth with regulated driven in sales was by in Our QA/QC across strength largely overall geographies major drug demands growth the our LC LC further markets. reinforcing of most
Our particularly, by of the biomedical weakness growth strong line business, we was in were mostly spec encouraged in product improvement the offset mass mass continue including show spec In to stabilization spectrometry our by signs continued fourth portfolio. mass high-resolution in research. our pharma in which quarter,
our open reliable serving also it system we begin an generation screening is clinical with launched the robust platform diagnostic proven clinical integrated use recently and Waters' needs fully quarter, the performance the shipping screening bench-top upon XX newborn RenataDX, general system general years experience throughput of builds high diagnostics. of This for During laboratories. and and next
our model. revenues, Waters' multiple our business strength grew chemistries, XXXX We was driven chemistries and of service were grew plans, our columns which Leading revenues recurring nature mass This in combination X% performance year-over-year, service our of continued are emphasizing application UPLC the quarter. and spec across further precision forward X% product strength recurring global the recurring the categories. in to further Bioseperations columns. reflect kits, in this strengthening looking branded which line in by
For base X%, strong of both the revenues chemistry year, rates instruments. Waters' the our in indicative installed for of full utilization service grew
sales system the both for service line. X% QX grew increased and to Turning for by instrument year. in TA product the Sales TA XX%. our fourth and full quarter increased X%
sales There across system grew full product and X% instrument was the For thermal lines year. and rheology our key grew full electroforce analysis, for and year, quarter service in broad-based the the growth TA sales X%.
as paying the in while to key are the thermal TA liquid the of our momentum in product in note, we I'm geographies. improving And I our We by in as continue business. year XXXX and well still strong all categories, the at discipline products line cycle that see lines but and discovery quarter expectations maintained earnings strength our TA our and pleased in attention with strengthening performance P&L, macro conditions operating on we analyzers. In and both market early investing in for are heavily encouraged industrial the to R&D strength the China exceeding markets, was we the States. United summary, of affecting looking particularly pharmaceutical chromatography category, along, year. the close broader in ended Furthermore, dynamic our Waters relatively high product
start Looking X ahead we focused value executing steadfastly to our model. point like XXXX, I'd reiterating remain on to on that creation by
driven improvement; attractive disciplined continues value second, a regularly with team. holding we for performance shareholder clear a seeking strategy position by in fourth, to a operating third, innovation; and being and create As culture first allocator; we capital leadership the structurally communicated, differentiated management by oriented markets; executing organic operational and opportunity the growth highly aim focused fifth,
page have ahead. what looking turned I'm We to and to the lays XXXX now truly forward
further XXXX Sherry on key provide will for detail, While our factors. is four outlook based
capital and prioritize sales. very optimize and balance development, also forth, of end business have the robust product continued we more introduction our cycle; positive to off on innovation our X%, sheet to QX; assertively full than year enhanced to investments building more dynamics; particular, I'm invest product investing and continue the second, momentum we starts which and growing market our with generally In organic the in efforts, up R&D shareholders. with capital of benefits to includes about XXXX new coming faster First, return working third, plan, deployment consistently implementation the a grow excited a
continue significantly, supplement new of will benefit saw several systems an select that product product to XXXX, we have formula. internal increased in we in product so is for energized It launches pace evaluate the from to external efforts but overall major form we While looking be our organization new technologies development the for XXXX. foundation innovation that more our XXXX cycle. launching to our exciting We're
innovation biopharmaceutical critical for in the monitoring as LCMS current quality solution clearly customers large Our the by LCMS a efforts launch Waters' with multiple pace and molecule system the system. BioAccord yesterday's BioAccord purpose in fit designed of our innovation regulators increasing we requirements accelerating highlighted industry are The by seeing for is that attributes. are and applications. of
benefit history Waters workflows compliance. of in and in is productivity, now decision time first rich more making the effective time-of-flight improved data routine mass delivering regulatory enhanced the for spectrometry For
feedback already are We our through underway. a our early have we market. have from a serving amount long target Sales access customers channel program. positive activities invested received of significant robust this And in now
deeper our units Buck customer BioAccord Sherry like eagerly Day in and provide have our fourth on further Investor financials. to We'll shipped for Sherry? York New over pass We further February that, at of call review revenue detail a our and With to upcoming feedback already City. experience. on await XX, quarter I'd XXXX we the strategy
